Aisling Barry

Dr. Aisling Barry

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TSTeo Stanescu
Teo Stanescu
ASAndrea Shessel
Andrea Shessel
CCCathy Carpino-Rocca
Cathy Carpino-Rocca
ETEdward Taylor
Edward Taylor
OSOleksii Semeniuk
Oleksii Semeniuk
AHAli Hosni
Ali Hosni
Purpose: To describe a comprehensive workflow for MRI-guided online adaptive stereotactic body radiation therapy (SBRT) specific to upper gastrointestinal cancer patients with abdominal compression on a 1.5T MR-Linac system. Additionally, we discuss the workflow’s clinical feasibility and early experience in the case of 16 liver and pancreas patients. Methods: Eleven patients with liver cancer and five patients with pancreas cancer were treated with online adaptive MRI-guidance under abdominal compression. Two liver patients received single-fraction treatments; the remainder plus all pancreas cancer patients received five fractions. A total of 65 treatment sessions were investigated to provide analytics relevant to the online adaptive processes. The quantification of target and organ motion as well as definition and validation of internal target volume (ITV) margins were performed via multi-contrast imaging provided by three different 2D cine sequences. The plan generation was driven by full re-optimization strategies and using T2-weighted 3D image series acquired by means of a respiratory-triggered exhale phase or a time-averaged imaging protocol. As a pre-requisite for the clinical development of the procedure, the image quality was thoroughly investigated via phantom measurements and numerical simulations specific to upper abdominal sites. The delivery of the online adaptive treatments was facilitated by real-time monitoring with 2D cine imaging. Results: Liver 1-fraction and 5-fraction online adaptive session time were on average 80 and 67.5 min, respectively. The total session length varied between 70–90 min for a single fraction and 55–90 min for five fractions. The pancreas sessions were 54–85 min long with an average session time of 68.2 min. Target visualization on the 2D cine image data varied per patient, with at least one of the 2D cine sequences providing sufficient contrast to confidently identify its location and confirm reproducibility of ITV margins. The mean/range of absolute and relative dose values for all treatment sessions evaluated with ArcCheck were 90.6/80.9–96.1% and 99/95.4–100%, respectively. Conclusion: MR-guidance is feasible for liver and pancreas tumors when abdominal compression is used to reduce organ motion, improve imaging quality, and achieve a robust intra- and inter-fraction patient setup. However, the treatment length is significantly longer than for the conventional linac, and patient compliance is paramount for the successful completion of the treatment. Opportunities for reducing the online adaptive session time should be explored. As the next steps, dose-of-the-day and dose accumulation analysis and tools are needed to enhance the workflow and to help further refine the online re-planning processes.

1 August 2020 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
Aisling BarryAisling Barry
Aisling Barry
SASmith Apisarnthanarax
Smith Apisarnthanarax
GOGrainne M O'KAne
Grainne M O'KAne
GSGonzalo Sapisochin
Gonzalo Sapisochin
RBRobert Beecroft
Robert Beecroft
MHMaria Hawkins
Maria Hawkins

1 September 2017 in Practical Radiation Oncology
Verified
Journal Article
Closed access
Aisling BarryAisling Barry
Aisling Barry
AMAndrew McPartlin
Andrew McPartlin
PLPatricia Lindsay
Patricia Lindsay
LWLisa Wang
Lisa Wang
JBJames Brierley
James Brierley
LDLaura A. Dawson
Laura A. Dawson

6 June 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
Aisling BarryAisling Barry
Aisling Barry
JHJoelle Helou
Joelle Helou
ABAndrea Bezjak
Andrea Bezjak
RWRebecca Wong
Rebecca Wong
LDLaura A. Dawson
Laura A. Dawson
NANeill K.J. Adhikari
Neill K.J. Adhikari

1 March 2022 in Precision Cancer Medicine
Verified
Journal Article
Open access
PDF file
FAFares Azoury
Fares Azoury
SMShagun Misra
Shagun Misra
Aisling BarryAisling Barry
Aisling Barry
JHJoelle Helou
Joelle Helou
Role of radiation therapy in triple negative breast cancer: current state and future directions—a narrative review Fares Azoury, Shagun Misra, Aisling Barry, Joelle Helou

1 February 2018 in International Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
Aisling BarryAisling Barry
Aisling Barry
AFAnthony Fyles
Anthony Fyles
Stereotactic ablative body radiotherapy (SABR) has a role as definitive therapy in many tumor sites; however, its role in the treatment of breast cancer is less well explored. Currently, SABR has been investigated in the neoadjuvant and adjuvant setting with a number of ongoing feasibility studies. However, its use comes with a number of radiobiological and technical challenges that require further evaluation. We have learned much from other extracranial disease sites such as lung, brain, and spine, where definitive treatment with SABR has shown encouraging outcomes. In women with breast cancer, SABR may eliminate the need for invasive surgery, reducing healthcare costs and hospital stays and providing an additional curative option for early-stage disease. This poses the following question: is there a role for SABR as a definitive therapy in breast cancer?